Non Melanoma Skin Cancer Market

Global Market Study on Non-Melanoma Skin Cancer Treatment: Radiation Therapy to Remain Most Attractive Segment by Treatment Type During 2017 - 2025

Non-Melanoma Skin Cancer Treatment Market Segmented By Radiation Therapy, Chemotherapy, Photodynamic Therapy Treatment with Basal Cell Carcinoma, Squamous Cell Carcinoma Indication

  • August-2017
  • PMRREP3648
  • 201 Pages
  • Healthcare

Government initiatives to raise awareness of non-melanoma skin cancer

Non-melanoma skin cancer is usually treated as a simple lesion in the initial stages but if not treated properly, it can quickly mushroom and spread to other body parts. Government authorities and regulatory bodies are working overtime to educate people about non-melanoma skin cancer and its debilitating effect on the nation’s economy.

This is particularly in the developed world. For e.g. – Cancer Council Australia has unveiled the SunSmart program to raise awareness of non-melanoma skin cancer. This could not be done sooner as Australia suffers a great deal from non-melanoma skin cancer and has the highest prevalence in the APAC region.

The Australian Institute of Health and Welfare estimates that skin cancer is the largest cancer diagnosed in the country and nearly 1800 people lost their lives to it in 2016. The A&Z non-melanoma skin cancer treatment market is anticipated to be valued at more than US$ 705 Mn at the end of the forecast period making it larger than the rest of the APAC region combined.

Find Out More about the Report Coverage


Company Profiles

  • Almirall S.A.
  • Boehringer Ingelheim GmbH 
  • Bristol-Myers Squibb Company 
  • Eli Lilly and Company 
  • Elekta AB 
  • F. Hoffmann-La Roche Ltd. 
  • Merck & Co., Inc.
  • Novartis AG
  • Mylan NV 
  • Sun Pharmaceutical Industries Ltd.
  • Varian Medical Systems, Inc.
  • Sensus Healthcare 
  • iCAD, Inc.
  • Accuray, Inc.
  • Ion Beam Applications SA
  • Others.

Radiation therapy dominates non-melanoma skin cancer treatment market

Radiation therapy has a market share approaching 90% in the non-melanoma skin cancer treatment market in 2017 itself and is unlikely to cede this commanding position anytime soon. Radiation therapy has a value of approx. US$ 4.8 Bn by end 2025 making it considerably larger than both chemotherapy and photodynamic therapy. Within radiation therapy, external beam radiation therapy is currently the largest in terms of market value.

However, the highest CAGR of 9.6% for the period 2017-2025 is anticipated to be witnessed in the superficial radiation therapy segment as this newer treatment has relatively lesser side-effects making it preferable for patient health in the long run.

The market attractiveness of radiation therapy in the non-melanoma skin cancer treatment market is expected to be 2.7 and the development of portable radiation therapy devices should further propel the non-melanoma skin cancer treatment market.

non melanoma skin cancer treatment market

Customize this Report

Explore Intelligence Tailored to Your Business Goals.

Numerous complications linked to conventional radiation therapy

Radiation therapy is used to treat non-melanoma skin cancer lesions in cases where surgery is not possible such as the nose tip, eyelids, and other extremities. Unfortunately, radiation therapy causes serious side-effects depending on the treatment area size, radiation dose, and exposure duration. Some of the complications include edema, skin peeling, skin problems, and hair loss. All these challenges restrain the growth of radiation therapy in the non-melanoma skin cancer treatment market.

Market Research Methodology - Perfected through Years of Diligence

A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.

Get actionable insights on Ship Repair And Maintenance Services Market

Superficial radiation therapy adopted in clinics for lesser side-effects

The development of standalone radiation therapy machines has led to their widespread acceptance in dermatology clinics to treat non-melanoma skin cancer. These highly portable devices are used because they have comparatively lesser side-effects.

Sensus Healthcare has created SRT radiation therapy devices to treat non-melanoma skin cancer as they are a highly effective form of treatment with much lesser side-effects. These devices have the added benefit of being more economical compared to conventional radiation therapy devices. Sensus Healthcare has sold more than 300 superficial radiation therapy devices in the U.S. alone and this number is increasing by the day.

Explore Persistence Market Research’s expertise in promulgation of the business !

Non-Melanoma Skin Cancer Treatment Market – Taxonomy

Treatment Type

  • Radiation Therapy
    • External Beam Radiation Therapy
    • Electronic Brachytherapy
    • Superficial Radiation Therapy
  • Chemotherapy
  • Photodynamic Therapy


  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa


  • Basal Cell Carcinoma
  • Squamous Cell Carcinoma

End User

  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics

Media Release


Polycystic Ovarian Syndrome Drugs Market

Global polycystic ovary syndrome drugs market revenue is estimated to reach US$ 1,154.8 Mn by 2024, expanding at a CAGR of 4.6% during the forecast period 2016–2024.

Hyperthermia Treatment for Cancer Market

Global report starts with an executive summary that states the market overview with pertinent market numbers and forecasts along with the CAGR during 2017-2025.

Mesotherapy Market

The relentless quest to remain beautiful by baby boomers in developed as well as developing countries is expected to fuel the growth of the mesotherapy market..

Arbovirus Testing Market

Global market for arbovirus testing is estimated to reach around US$ 1500 Mn by 2025 end from a valuation of about US$ 970 Mn in 2017 with a moderate CAGR of 5.6%.

Our Clients

Our Clients